{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:03:02Z","timestamp":1787022182563,"version":"build-2736575974"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>This study aimed to determine if the drug-induced lymphocyte stimulation test (DLST) for various oral mesalamines can diagnose mesalamine intolerance and predict the success of retreatment in patients with adverse events (AEs) due to the first oral 5-aminosalicylate (5-ASA) formulations administered. Data from patients with ulcerative colitis who experienced AEs after administration of the first oral 5-ASA and underwent DLSTs for two or more types of mesalamine, including the first oral 5-ASA were retrospectively analyzed. Mesalamine intolerance was defined as AEs within 6 months of starting the first oral 5-ASA and the inability to take oral mesalamine. Clinical characteristics, symptoms, type of first oral 5-ASA, DLST results, and the efficacy of retreatment with oral mesalamine were compared. The DLST for the first oral 5-ASA (F-DLST), highest DLST among the different oral mesalamine types (H-DLST), and mean DLST (M-DLST) were analyzed. Twenty-eight patients (median age 39 years, 57.1% male) were eligible; six patients were tolerant to oral mesalamine and22 were intolerant. Positive F-DLST (odds ratio [OR], 2.300; p\u2009=\u20090.002), positive M-DLST (OR, 2.667; p\u2009=\u20090.007), and older age at diagnosis (median 24.5 vs. 41.5; p\u2009=\u20090.006) were associated with mesalamine intolerance. Fourteen of the 28 patients underwent mesalamine retreatment. Higher F-DLST (median 88.0 vs. 174.0; p\u2009=\u20090.026), M-DLST (median 118.5 vs. 170.3; p\u2009=\u20090.040), and older age at diagnosis (median 24.5 vs. 39.0; p\u2009=\u20090.033) were associated with retreatment failure for oral mesalamine. DLSTs for various oral mesalamine formulations may be useful in predicting mesalamine intolerance and retreatment outcomes. However, their clinical utility should be interpreted with caution due to the risk of false-positive and false-negative results.<\/jats:p>","DOI":"10.1371\/journal.pone.0334969","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:31:32Z","timestamp":1761845492000},"page":"e0334969","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Significance of the drug-induced lymphocyte stimulation test for various oral mesalamines in ulcerative colitis with mesalamine intolerance"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5876-2508","authenticated-orcid":true,"given":"Akira","family":"Madarame","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakatsu","family":"Fukuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Ichimiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiko","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Morise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Itoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"4","key":"pone.0334969.ref001","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ajg.2011.67","article-title":"Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis","volume":"106","author":"AC Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"pone.0334969.ref002","article-title":"Oral 5-aminosalicylic acid for the induction of remission in ulcerative colitis","volume":"12","author":"M Alistair","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"pone.0334969.ref003","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/00365528209182073","article-title":"Sulfasalazine intolerance: a retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease","volume":"17","author":"OH Nielsen","year":"1982","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"pone.0334969.ref004","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/j.1572-0241.2005.41442.x","article-title":"Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies","volume":"100","author":"FS Velayos","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"pone.0334969.ref005","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/gut.28.5.613","article-title":"Salicylate induced exacerbation of ulcerative colitis","volume":"28","author":"TK Chakraborty","year":"1987","journal-title":"Gut"},{"key":"pone.0334969.ref006","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/0016-5085(95)90154-X","article-title":"Exacerbation of chronic ulcerative colitis with mesalamine","volume":"108","author":"JB Sturgeon","year":"1995","journal-title":"Gastroenterology"},{"issue":"6","key":"pone.0334969.ref007","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/gut.37.6.838","article-title":"Mesalazine induced exacerbation of ulcerative colitis","volume":"37","author":"KC Kapur","year":"1995","journal-title":"Gut"},{"issue":"6921","key":"pone.0334969.ref008","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/bmj.308.6921.113","article-title":"Fever, vasculitic rash, arthritis, pericarditis, and pericardial effusion after mesalazine","volume":"308","author":"AG Lim","year":"1994","journal-title":"BMJ"},{"issue":"4","key":"pone.0334969.ref009","first-page":"435","article-title":"Massive pericardial effusion in a child following the administration of mesalamine","volume":"25","author":"GC Kaiser","year":"1997","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"pone.0334969.ref010","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/00054725-200309000-00004","article-title":"Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations","volume":"9","author":"RA Foster","year":"2003","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"pone.0334969.ref011","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00004836-199701000-00007","article-title":"Mesalamine-induced hypersensitivity pneumonitis: a case report and review of the literature","volume":"24","author":"S Sviri","year":"1997","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"pone.0334969.ref012","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/jgh.15138","article-title":"Multicenter survey on mesalamine intolerance in patients with ulcerative colitis","volume":"36","author":"S Hiraoka","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"pone.0334969.ref013","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/apt.16120","article-title":"5-aminosalicylate-intolerant patients are at increased risk of colectomy for ulcerative colitis","volume":"53","author":"S Hibiya","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0334969.ref014","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3862\/jcoloproctology.67.259","article-title":"Desensitization therapy for mesalazine-intolerant patients with inflammatory bowel disease","volume":"67","author":"T Fukushima","year":"2014","journal-title":"J Jpn Soc Coloproctol"},{"issue":"2","key":"pone.0334969.ref015","doi-asserted-by":"crossref","DOI":"10.1002\/ibd.21323","article-title":"New desensitization regimen with mesalamine granules in a patient with ulcerative colitis and mesalamine intolerance","volume":"17","author":"P Oustamanolakis","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"pone.0334969.ref016","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s12328-016-0675-2","article-title":"Mesalazine allergy in a boy with ulcerative colitis: clinical usefulness of mucosal biopsy criteria","volume":"9","author":"S Wada","year":"2016","journal-title":"Clin J Gastroenterol"},{"issue":"12","key":"pone.0334969.ref017","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.3390\/jcm8122109","article-title":"Switching between three types of mesalazine formulation and sulfasalazine in patients with active ulcerative colitis who have already received high-dose treatment with these agents","volume":"8","author":"E Yasutomi","year":"2019","journal-title":"J Clin Med"},{"issue":"2","key":"pone.0334969.ref018","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2222.1997.tb00690.x","article-title":"The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity","volume":"27","author":"B Nyfeler","year":"1997","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"pone.0334969.ref019","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1078\/0944-7113-00141","article-title":"Incidence and clinical features of liver injury related to Kampo (Japanese herbal) medicine in 2,496 cases between 1979 and 1999: problems of the lymphocyte transformation test as a diagnostic method","volume":"9","author":"N Mantani","year":"2002","journal-title":"Phytomedicine"},{"key":"pone.0334969.ref020","first-page":"46","article-title":"Low specificity of the lymphocyte stimulation test for methotrexate in patients with rheumatoid arthritis","volume":"26","author":"K Hagiwara","year":"2006","journal-title":"Allergy Pract"},{"issue":"2","key":"pone.0334969.ref021","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5217\/ir.2018.16.2.273","article-title":"Evaluation of the drug-induced lymphocyte stimulation test for diagnosing mesalazine allergy","volume":"16","author":"D Saito","year":"2018","journal-title":"Intest Res"},{"issue":"2","key":"pone.0334969.ref022","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/00365521.2021.1998601","article-title":"Classification and clinical features of adverse drug reactions in patients with ulcerative colitis treated with 5-aminosalicylate acid: a single-center, observational study","volume":"57","author":"Y Tsujii","year":"2022","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"pone.0334969.ref023","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s12328-020-01216-2","article-title":"Mesalazine formulation intolerance due to suspected excipient allergy in the treatment of ulcerative colitis: a case report","volume":"13","author":"Y Arai","year":"2020","journal-title":"Clin J Gastroenterol"},{"issue":"3","key":"pone.0334969.ref024","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3164\/jcbn.22-33","article-title":"Retrospective investigation of mesalamine intolerance in patients with ulcerative colitis","volume":"71","author":"Y Minagawa","year":"2022","journal-title":"J Clin Biochem Nutr"},{"issue":"10","key":"pone.0334969.ref025","first-page":"22176","article-title":"Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease","volume":"17","author":"M Satohiro","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"pone.0334969.ref026","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/ped.13235","article-title":"5-Aminosalicylate intolerance causing exacerbation in pediatric ulcerative colitis","volume":"59","author":"H Shimizu","year":"2017","journal-title":"Pediatr Int"},{"issue":"3","key":"pone.0334969.ref027","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00535-018-1439-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease","volume":"53","author":"K Matsuoka","year":"2018","journal-title":"J Gastroenterol"},{"issue":"1","key":"pone.0334969.ref028","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000527452","article-title":"Significance of 5-aminosalicylic acid intolerance in the clinical management of ulcerative colitis","volume":"104","author":"Y Mikami","year":"2023","journal-title":"Digestion"},{"issue":"2","key":"pone.0334969.ref029","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3390\/jcm10020364","article-title":"Dermatological manifestations in inflammatory bowel diseases","volume":"10","author":"E Antonelli","year":"2021","journal-title":"J Clin Med"},{"issue":"5","key":"pone.0334969.ref030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.09.033","article-title":"Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network meta-analysis","volume":"22","author":"SS Mattay","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"pone.0334969.ref031","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000367862","article-title":"Previous cancer and\/or lymphoma in patients with refractory IBD: anti-TNF or conventional immunosuppressive treatment","volume":"32","author":"JM Gerassimos","year":"2014","journal-title":"Dig Dis"},{"issue":"1","key":"pone.0334969.ref032","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/ibd\/izab004","article-title":"Genetic background of mesalamine-induced fever and diarrhea in Japanese patients with inflammatory bowel disease","volume":"28","author":"K Suzuki","year":"2022","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"pone.0334969.ref033","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5217\/ir.2019.00084","article-title":"5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis","volume":"18","author":"S Mizuno","year":"2020","journal-title":"Intest Res"},{"issue":"8","key":"pone.0334969.ref034","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1398-9995.2004.00547.x","article-title":"The lymphocyte transformation test in the diagnosis of drug hypersensitivity","volume":"59","author":"WJ Pichler","year":"2004","journal-title":"Allergy"},{"issue":"10","key":"pone.0334969.ref035","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2957\/kanzo.48.517","article-title":"Recent status of drug-induced liver injury: an analysis of 366 cases between 2002 and 2006","volume":"48","author":"H Takikawa","year":"2007","journal-title":"Kanzo"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334969","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:31:40Z","timestamp":1761845500000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334969"}},"subtitle":[],"editor":[{"given":"Mohammed","family":"Misbah Ul Haq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0334969","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}